Highlights of US CDER drug safety activity in 2003

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2004年 / 1005卷 / 1期
关键词：
Public Health; Medication Error; Product Testing; Drug Evaluation; Prescription Medicine;
D O I：
10.2165/00128415-200410050-00005
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3 / 3
相关论文
共 50 条
  • [41] The US drug safety system: role of the pharmaceutical industry
    Gibson, Brent R.
    Suh, Ryung
    Tilson, Hugh
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (02) : 110 - 114
  • [42] How the US drug safety system should be changed
    Strom, BL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (17): : 2072 - 2075
  • [43] Report on Drug Safety and the US FDA by the Institute of Medicine
    Anthony W. Fox
    International Journal of Pharmaceutical Medicine, 2006, 20 (5) : 289 - 291
  • [44] US FDA enhancing postmarketing drug safety surveillance
    Reactions Weekly, 2019, 1780 (1) : 3 - 3
  • [45] US FDA Enhancing Postmarketing Drug Safety Surveillance
    不详
    PHARMACEUTICAL MEDICINE, 2020, 34 (01) : 64 - 64
  • [46] US FDA reports new steps in drug safety
    Reactions Weekly, 2007, 1138 (1) : 3 - 3
  • [47] Drug safety provisions in US and Europe outshine Canada
    Silversides, Ann
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (01) : E23 - E24
  • [48] US FDA 2009 drug safety warnings analysed
    Reactions Weekly, 2012, 1388 (1) : 4 - 4
  • [49] Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER
    Alexei C. Ionan
    Jennifer Clark
    James Travis
    Anup Amatya
    John Scott
    James P. Smith
    Somesh Chattopadhyay
    Mary Jo Salerno
    Mark Rothmann
    Therapeutic Innovation & Regulatory Science, 2023, 57 : 436 - 444
  • [50] Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER
    Ionan, Alexei C. C.
    Clark, Jennifer
    Travis, James
    Amatya, Anup
    Scott, John
    Smith, James P. P.
    Chattopadhyay, Somesh
    Salerno, Mary Jo
    Rothmann, Mark
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (03) : 436 - 444
12345